F. Saad

Chronic inflammation is negatively associated with prostate cancer and high‐grade prostatic intraepithelial neoplasia on needle biopsy

L. Bégin, F. Bénard, P. Karakiewicz, 2007, International journal of clinical practice.

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

C. Sternberg, M. Hussain, F. Saad, 2022, ESMO Open.

Bone Complications in Prostate Cancer: Current and Future Role of Bisphosphonates

J. Moul, F. Saad, 2005, Current Oncology.

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

Macie J. Rubin, M. Rubin, M. Sydes, 2023, European journal of cancer.

NF‐κB nuclear localization and its prognostic significance in prostate cancer

L. Lessard, A. Mes-Masson, F. Saad, 2003 .

Trial Participation is Not Associated with Better Biochemical Recurrence-free Survival in a Large Cohort of External Beam Radiotherapy-Treated Intermediate- and High-Risk Prostate Cancer Patients.

P. Karakiewicz, D. Taussky, G. Delouya, 2022, Clinical oncology (Royal College of Radiologists (Great Britain)).

LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)

M. Parmar, M. Sydes, C. Parker, 2022, Annals of Oncology.